To exploit the potential of PPARs as drug targets for cancer, we will require a more nuanced understanding of the role of specific PPAR isoforms in specific cancers, as well as means to identify patient groups who might benefit from therapeutics targeting PPARs. This evidence concerns the gene PPARA and cancer.